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1. Introduction 
Increasing prevalence of pulmonary diseases with high mortality and morbidity such as 
chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, infectious diseases, 
tuberculosis and lung cancer, makes pulmonary drug delivery as a non-invasive and 
attractive approach for the local drug administration and treatment of these pathologies 
(Marianecci et al., 2011). In this case, lower dosages than by the oral route can be used with 
comparable effectiveness which will reduce unwanted side effects (Timsina et al., 1994).The 
lung also provides a non-invasive route of delivery for the systemic circulation, due to its 
unique characteristics such as large surface area, thin epithelial barrier and high blood flow. 
Lack of first pass metabolism and less enzymatic activity make pulmonary delivery as an 
ideal administration route for extensively degraded drugs following oral delivery and for 
macromolecules, such as proteins and peptides, respectively(Hamishehkar et al., 2010; 
Rytting et al., 2008; Sakagami, 2006). Following approving the first inhaled therapeutic 
macromolecule for systemic delivery, human insulin (Exubera™) by the Food and Drug 
Administration (FDA) and the European Agency for the Evaluation of Medicinal Products 
in 2006, the scientific community look for other candidates that would benefit from 
pulmonary delivery for systemic action (Patton et al., 2004; Furness, 2005). In contrast to 
injection therapy, inhalation therapy is not associated with pain and this should increase 
patient comfort and compliance, causing improved treatment outcome (Laube, 2005). Drug 
deposition in the lung is mainly controlled by its aerodynamic diameter (Wolff et al., 1993). 
Particles larger than 5 μm are mostly trapped by oropharyngeal deposition and incapable of 
reaching the lungs while smaller than 1 μm are mostly exhaled without deposition  
(Sakagami, 2006). Particles with aerodynamic diameters between 1 and 5 μm are expected to 
efficiently deposit in the lung periphery (Heyder et al., 1986). The effective inhalation 
performance of dry-powder products is dependent on the drug formulation and the inhaler 
device. Dry powder formulations are usually prepared by mixing the micronized drug 
particles with larger carrier particles. The aerosolization efficiency of a powder is highly 
dependent on the carrier characteristics, such as particle size distribution, shape and surface 
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properties. The main objective in the inhalation field is to achieve reproducible, high 
pulmonary deposition. This could be achieved by successful carrier selection and careful 
process optimization (Pilcer et al., 2012). Therefore, the purpose of this chapter is to review 
the used carriers in inhalable formulations, their production and the impact of the 
physicochemical properties of carriers on carrier-drug dispersion is discussed in detail. This 
chapter offers a perspective on current reported studies to modify carrier for its better 
performance. Several methodologies have been discussed. 
2. Dry powder inhalers 
Pressurized metered-dose inhaler (MDI), nebulizer and dry powder inhaler (DPI) are main 
delivery systems in pulmonary delivery (Timsina et al., 1994). Among these, DPI appears to 
be the most promising for future use (Todo et al., 2001).They are propellant-free, portable, 
easy to operate and low-cost devices with improved stability of the formulation as a result 
of the dry state(Carpenter et al., 1997; Prime et al., 1997).Spinhaler®, the first dry powder 
inhaler, came into the market in 1970 and since then a new are started in the subject of 
pulmonary drug delivery. Dry powder inhalers and dry powder inhalation technology 
became the second most frequently used inhalation devices for pulmonary drug 
administration after Montreal Protocol in 1987 in limitation of using CFC in products. Dry 
powder inhalers have even become the first choice of inhalation devices in European 
countries (Marriott et al., 2012).They are a widely accepted inhaled delivery dosage form 
where they are currently used by an estimated 40% of patients to treat asthma and chronic 
obstructive pulmonary disease (Atkins, 2005). Using the DPI system, respiratory delivery of 
potent drugs such as insulin (Edwards et al., 1997), antibiotics (Geller et al., 2007; Hickey et 
al., 2006), drugs for neurological disorders like Parkinson’s disease(Stoessl, 2008), 
antituberculosis (Anon, 2008), antihypertensive nifedipine( Plumley et al., 2009), anticoagulant 
heparin (Rawat et al., 2008),drugs for sexual dysfunction (Cheatham et al., 2006), opioids and 
fentanyl for cancer pain (Farr et al., 2006; Kleinstreuer et al., 2008; Fleischer et al., 2005) and 
delivery of atropine sulphate nanoparticle as an antidote for organophosphorus poisoning 
with better bioavailability (Ali et al., 2009) have been studied. DPI formulations of measles 
vaccine (LiCalsi et al., 2001), mucosal vaccination for influenza virus (Edwards et al., 2005), 
have all been studied with considerable achievement. DPIs have to overcome various physical 
difficulties for effective drug delivery either local or systemic purposes (Prime et al., 1997). 
First, small size of inhalable particles subjected them to forces of agglomeration and cohesion, 
resulting in poor flow and non-uniform dispersion (Crowder et al., 2002). 
3. The role of carrier on DPI performance  
DPI is generally formulated as a powder mixture of coarse carrier particles and micronized 
drug particles with aerodynamic particle diameters of 1–5 μm (Iida et al., 2003). Carrier 
particles are used to improve drug particle flowability, thus improving dosing accuracy and 
minimizing the dose variability observed with drug formulations alone while making them 
easier to handle during manufacturing operations (Timsina et al., 1994; Schiavone et al., 
2004). With the use of carrier particles, drug particles are emitted from capsules and devices 
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more readily, hence, the inhalation efficiency increases (Iida et al., 2001). Moreover, usually 
no more than a few milligrammes of a drug needs to be delivered (e.g., between 20 μg and 
500 μg of corticosteroids for asthma therapy), and thus carrier provides bulk, which 
improves the handling, dispensing, and metering of the drug (Pilcer et al., 2012). The 
presence of the carrier material is the taste/sensation on inhaling, which can assure the 
patient that a dose has been taken (Prime et al., 1997).Consequently, the carrier forms an 
important component of the formulation and any change in the physico-chemical properties 
of the carrier particles has the potential to alter the drug deposition profile (Zeng et al., 
2000). Therefore, the design of the carrier particle is important for the development of dry 
powder inhalations (Hamishehkar et al., 2010). Carrier particles should have several 
characteristics such as physico-chemical stability, biocompatibility and biodegradability, 
compatible with the drug substance and must be inert, available and economical. During 
insufflation, the drug particles are detached from the surface of the carrier particles by the 
energy of the inspired air flow that overcomes the adhesion forces between drug and carrier. 
The larger carrier particles impact in the upper airways, while the small drug particles go 
through the lower parts of lungs (Pilcer et al., 2012). Unsatisfactory detachment of drug from 
the carrier due to strong inter-particulate forces may be one of the main reasons of inefficient 
drug delivery encountered with most DPIs (Zeng et al., 2000; Zhou et al., 2011). Therefore, in 
the best case, the adjusted balance between adhesive and cohesive forces provides enough 
adhesion between drug and carrier to produce a stable formulation (homogeneous mixture 
with no powder segregation and proper content uniformity) yet allows for easy separation 
during inhalation. Consequently, it has been stated that the efficiency of a DPI formulation is 
extremely dependent on the carrier characteristics and the selection of carrier is a crucial 
determinant of the overall DPI performance (Pilcer et al., 2012). Obviously, the effect of the 
carrier material on DPI formulation should be carefully evaluated. The range of materials 
which can be proposed to be as carriers in inhaled products are restricted for toxicological 
reasons. Lactose and other sugars have been studied and used, therefore modifications to these 
materials may allow further formulation optimization (Prime et al., 1997).  
4. Inhaler testing equipments 
Cascade impactors operate on the base of inertial impaction. Each stage of the impactor 
contains a single or series of nozzles or jets through which the sample laden air is drawn 
directing any airborne particles towards the surface of the collection plate for that particular 
stage. Whether a particular particle impacts on that stage is dependent on its aerodynamic 
diameter. Particles having sufficient inertia will impact on that particular stage collection 
plate whilst smaller particles with insufficient inertia will remain entrained in the air stream 
and pass to the next stage where the process is repeated. The stages are normally assembled 
in a stack in order of decreasing particle size. As the jets get smaller, the air velocity 
increases and finer particles are collected. Any remaining particles are collected on an after 
filter (or by a –Micro-Orifice Collector). The term 'Impactor' is generally used for an 
instrument where the particles 'impact' on a dry impaction plate or cup. If the collection 
surface is liquid, as in the case of the Multi-Stage Liquid Impinger (MSLI), then the term 
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'impinger' is used. The general principles of inertial impaction apply to both 'impactors' and 
'impingers'. The US and European Pharmacopoeia list no less than five different cascade 
impactors/impingers suitable for the aerodynamic assessment of fine particles. However, 
only the Andersen Cascade Impactor (ACI), the Next Generation Impactor (NGI) and the 
Multi-Stage Liquid Impinger (MSLI) appear in both pharmacopoeia. In research applications, 
in vitro/in vivo correlation and bioequivalence may be important and so detailed particle size 
data may be required. In routine quality control, where the concern is batch-to-batch variation 
a coarser test may be acceptable. The Glass Twin Impinger, for example has been retained as 
Apparatus A in the European Pharmacopoeia, because of its value as a simple and inexpensive 
quality control tool. In general however, it is accepted that an Impactor/impinger should have 
a minimum of five stages and preferably more, if it is to provide detailed particle size 
distribution data. The aerodynamic particle size distribution of the drug leaving an inhaler 
device can define the manner in which an aerosol deposits in the respiratory tract during 
inhalation. This characteristic of the aerosol is often used in judging inhaler performance and is 
particularly relevant in the development of inhalation formulations during research, 
production, quality assurance and equivalency testing. The results of characterizations using 
cascade impaction techniques are additionally used for the determination of fine particle 
fraction or fine particle dose which may be correlated to the dose or fraction of the drug that 
penetrates to the lung during inhalation by a patient. Dry Powder Inhaler (DPI) testing could 
require added options for preventing stage overloading and necessary to achieve the specified 
pressure drop through the device. Upper stage mass overloading can be prevented with the 
addition of a high capacity preseparator or pre-collector. The feature traps non-inhalable 
aerosols. To achieve the proper pressure drop of 4 kPa (40.8 cm water) in the inhaler, a higher 
vacuum flow rate at 60 or 90 L/minute may be needed.Impactors/impingers are specifically 
designed to meet the highest criteria laid down in the various Pharmacopoeia (e.g. United 
States Pharmacopeia Chapter <601>; European Pharmacopoeia Chapter 29.9.18 for 
characterizing aerosol clouds emitted by inhalers). By analyzing the drug deposited on the 
individual stages and the final filter, the Fine Particle Fraction (FPF), the Fine Particle Dose 
(FPD), the Mass Median Aerodynamic Diameter (MMAD) and Geometric Standard Deviation 
(GSD) can all be calculated (The Copley Scientific Limited, 2010). 
5. Expressions used to define drug lung deposition 
The American and European pharmacopoeias have explained methods based on inertial 
impaction to assess the in vitro inhalation performance of formulations by determination of 
the fine particles (Pilcer et al., 2012). 
5.1. Fine Particle Dose (FPD) and fine particle fraction (FPF) 
The aerodynamic evaluation methods of fine particles permit the determination of the fine-
particle dose (FPD), which corresponds to the mass of drug particles that have an 
aerodynamic diameter less than 5 μm. Such particles can theoretically be deposited in the 
deep lung after inhalation. The fine-particle fraction (FPF), which is the percentage of the 
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FPD usually related to either the nominal dose (total drug mass contained in the device) or 
the recovered drug (sum of the drug collected in the device and in the different parts of the 
impingers or impactors after inhalation) (Pilcer et al., 2012). 
5.2. Emitted dose 
The emitted dose expresses the drug mass exiting the device after inhalation. In some cases, 
FPF can be calculated from emitted dose instead of total or recovered dose of drug from 
impingers or impactors. The ability of the powder to be fluidised by the airflow through an 
inhaler is usually indicated by the emission dose, whilst the FPD and FPF measure the 
capability of the formulation to be fluidised and deagglomerated in time to release the drug 
from the carrier to be deposited in the appropriate level of the impactors and impingers 
(Pilcer et al., 2012). 
5.3. Dispersibility 
The dispersibility is calculated as the ratio of FPD to emitted dose (Zeng et al., 2000). 
5.4. Mass median aerodynamic diameter (MMAD) 
Mass median diameter of an aerosol means the particle diameter that has 50% of the aerosol 
mass residing above and 50% of its mass below it. The concept of aerodynamic diameter is 
central to any aerosol measurements and respiratory drug delivery. The aerodynamic 
diameter relates the particle to the diameter of a sphere of unit density that has the same 
settling velocity as the particle of interest regardless of its shape or density. The mass–mean 
aerodynamic diameter (MMAD) is read from the cumulative distribution curve at the 50% 
point (Labiris et al., 2003).The theoretical mass–mean aerodynamic diameter (daero) was 
determined from the geometric particle size and tap density using the following 
relationship:  
0.5( / )ref
aero geod d
ρ ρ
γ
  =   
 
Where dgeo=geometric diameter, γ=shape factor (for a spherical particle, γ=1), ρ=particle bulk 
density and ρref=water mass density (1 g/cm3). Tapped density measurements underestimate 
particle bulk densities since the volume of particles measured includes the interstitial space 
between the particles. The true particle density, and the aerodynamic diameter of a given 
powder, is expected to be slightly larger than reported (El-Gendy et al., 2009). 
5.5. Geometric standard deviation (GSD) 
The degree of dispersity is an important consideration for both quality and efficacy of 
pharmaceutical aerosols (Chew et al., 2002). The nature of the aerosol distribution must be 
established accurately if its implications for deposition and efficacy are to be understood  
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(Telko et al., 2005). The degree of dispersion in a lognormally distributed aerosol is 
characterized by the geometric standard deviation (GSD). A larger GSD implies a longer 
large particle size tail in the distribution(Musante et al., 2002). GSD for a well-functioning 
stage should ideally be less than 1.2 (the GSD for an ideal size fractionators would be 1.0 
and indicates a monodisperse aerosol) (Marple et al., 2003). GSD is a measure of the 
variability of the particle diameters within the aerosol and is calculated from the ratio of the 
particle diameter at the 84.1% point on the cumulative distribution curve to the MMAD. For 
a log-normal distribution, the GSD is the same for the number, surface area or mass 
distributions (Labiris et al., 2003). The GSD was determined as  
sizes X
GSD
sizes Y
=  
where sizes X and Y are particle sizes for which the line crosses the 84% and 16% mark, 
respectively (Emami et al., 2009).Mostly, particle size distributions are log-normal, for which 
type of distributions the geometric mean diameter (GMD) and GSD are frequently used as 
the characteristic parameters. Aerosols from dry powder inhalers are not log-normal 
however, because they are nearly always a mixture of primary and secondary particles. 
Agglomerates in the aerosol are the reason for a tail-off at the side of the larger diameters. 
Therefore, the mass median diameter is a better parameter, although the size fraction for 
which mass median diameter is calculated should be defined also. For inhalation drugs, the 
mass median aerodynamic diameter (MMAD) is the most frequently used 
parameter(Bosquillon et al., 2001).  
6. Carrier qualifications for application in DPIs 
6.1. Carrier size 
Different and controversy reports have been published about the suitable carrier size for 
inhalation purposes. Some previous studies have reported improvements in the amount of 
respirable drug delivered from a DPI by way of reducing the particle size of the carrier 
(Steckel et al., 1997; Gilani et al., 2004; Louey et al., 2003). For example, increased respirable 
fraction of salbutamol sulphate (Kassem et al., 1989; Zeng et al., 2000), terbutaline (Kassem 
et al., 1989), disodium chromoglycate(Braun et al., 1996) and budesonide (Steckel et al., 1997) 
were concluded with decreased carrier size. It was proposed that smaller agglomerates meet 
more forceful shear in the turbulent airstreams causing more effective deagglomeration 
(Islama et al., 2012). However, the use of too small a carrier will result in poor flow 
properties of the powder, which is one of the primary reasons for incorporating a coarse 
carrier within the formulation (Zeng et al., 2001).On the other hand, it was reported that 
larger carrier particles, normally exhibit larger surface discontinuities than fine crystals (De 
Boer et al., 2003). This may have the advantage of providing shelter to drug particles from 
the press-on forces during mixing, as the drug particles tend to assemble in these 
discontinuities during mixing (Iida et al., 2003; De Boer et al., 2005). Therefore, a high carrier 
particle size does not necessarily have a negative effect on the drug deposition profiles after 
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inhalation (Hamishehkar et al., 2010). In a study, formulations of respirable recombinant 
human granulocyte-colony stimulating factor with larger carriers (90–125 μm) showed a 
higher drug dispersion than the same formulation with 38–75 μm carriers, and it is 
interpreted that this is due to the lower inter-particle forces among the larger sized particles 
(French et al., 1996). Similar results was shown for enhanced inhalation performance of 
terbutaline sulphate from a formulation containing coarse lactose (53–105 μm) than the same 
drug containing fine lactose carriers with size less than 53 μm (Byron et al., 1990). Recently, 
an increase in carrier size resulted better aerosolisation behavior of insulin loaded PLGA 
microparticles mixed with mannitol carrier. The authors conclude that the use of larger 
particles of mannitol carrier with a lower carrier/microcapsule ratio leads to higher 
dispersion of the drug due to increase flowability (Hamishehkar et al., 2010). 
6.2. Carrier shape 
Although the influence of carrier particle shape on the drug dispersibility from the DPI 
formulation is not well recognized but it is known that the attractive forces between drug 
and carrier particles can be shape dependent (Mullins et al., 1992; Crowder et al., 2001). In 
fact most commonly used particles for DPI formulations have irregular shapes. In vitro 
inhalation studies have indicated that elongated (Larhrib et al., 2003; Zeng et al., 2000), 
needle-like (Ikegami et al., 2002), porous and wrinkled particles (Chew et al., 2005)have 
improved lung deposition properties of various formulations. Increasing the elongation ratio 
of the lactose carrier particles also appeared to increase the FPF of salbutamol sulphate (Zeng 
et al., 2000).Recently, it was reported pollen-shaped hydroxyapatite carrier increased 
dispersibility of budesonide particles due to reduction in particle interactions (Hassan et al., 
2010; 2010). Definitely surface shape effects agglomeration strength but it was also discussed 
that the aerodynamic diameter of the agglomerates can be changed by shape factor. Because of 
their larger shape factor, elongated particles have a smaller aerodynamic diameter than 
spherical particles and thus agglomerations of active drug particles and elongated carriers 
remain aerosolized for a longer time, and greater distance along the inhalation path, then 
deagglomeration is enhanced (Islama et al., 2012). The figure 1 shows the presence of loose 
agglomerates in freeze dried mannitol samples adapted from reference (Hamishehkar et al., 
2010), applied mannitol particles in different shapes for formulation of DPI form of insulin-
loaded biodegradable polymeric microparticles. Spray dried and freeze dried mannitol, both 
showed smooth surfaces while formulation composed of freeze dried mannitol showed higher 
FPF and emitted dose than spray dried mannitol. This was interesting when it was found that 
spray dried mannitol had lower true density than freeze dried mannitol, possible resulting in 
better emitted dose and consequently improved FPF. This aerosolization behavior of freeze 
dried mannitol can be attributed to its needle shape particle morphology. Spatial hindering 
effect of rod shape particles can lead their easier aerosolization, and hence higher emission and 
higher FPF. The results of FPF and emitted dose for different formulations can partially be 
explained by elongation ratio and shape factors reported in this article. Freeze dried mannitol 
had higher elongation ratio and lower shape factor than spray dried mannitol which indicates 
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more irregular shape. In vitro inhalation studies have indicated that elongated, fibrous 
particles improve lung deposition properties (Chan et al., 1989; Fults et al., 1997). 
 
Figure 1. Scanning electron micrographs of freeze-dried mannitol (FDM) (a, b) and schematic image of 
formed loose agglomerates of needle shape FDM particles (c) adapted from reference (Hamishehkar et 
al., 2010) 
6.3. Carrier surface 
The in vitro inhalation properties of DPI are reported to be related to the surface properties 
of the carrier particles (Zeng et al., 2000; Heng et al., 2000; Iida et al., 2001; 2003). Surface 
morphology has been demonstrated to directly influence the contact area between drug 
particle and carrier, leading to variations in interparticulate adhesion. Several studies have 
reported that variations in contact area, as a result of differing surface structure, could 
potentially compromise the aerosolization performance of the drug particles (Zeng et al., 
2000; Flament et al., 2004; Young et al., 2002). Some surface modifications of carrier particles 
have been reported to improve inhalation performance of DPI (Kawashima et al., 1998; Chan 
et al., 2003). Previous investigations reported that the carrier surface morphology directly 
affected the aerosolization efficiency from a DPI (Podczeck, 1998; Larhrib et al., 1999). In 
general terms, a decrease in roughness is believed to improve aerosolization efficiency of a 
drug-carrier blend (Ganderton et al., 1992; Kawashima et al., 1998; Zeng et al., 2001). 
However, it was shown that coarse carrier particles which normally exhibit large surface 
discontinuities may provide shelter to drug particles from the press-on forces during 
mixing, as the drug particles tend to assemble in these discontinuities during mixing (Iida et 
al., 2003). Therefore, high carrier rugosity drug-to-carrier interaction (Kawashima et al., 
1998; Podczeck, 1998; Zeng et al., 2000). These interaction forces have to be strong enough to 
guarantee good mixture stability during handling and proper drug deaggregation does not 
necessarily have a negative effect on the drug detachment from carrier crystals during 
inhalation, providing that inertial detachment forces are applied. Chan et al. also reported 
that a positive linear trend was established between the roughness of the lactose surface and 
the FPF and dispersibility of the drug (Chan et al., 2003). Therefore, an important balance 
between the surface morphologies of both the drug and carrier can exist (Young et al., 2002). 
It was shown by Heng et al. that an optimum lactose surface roughness (Ra) was required 
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for an increased fine particle fraction of salbutamol sulphate (Heng et al., 2000). All these 
studies demonstrated that the different surface roughness of the carrier led to different 
adhesion forces between the drug and carrier, which was reflected in the in vitro deposition 
results. The carrier surface plays an important role in, but weak enough to enable the 
separation forces during inhalation to detach a substantial fraction of the drug dose from the 
carrier crystals. This requires that the size distributions of the interaction forces (during 
mixing) and separation forces (during inhalation) are balanced properly (De Boer et al., 
2003).The assumed role of carrier surface on the separation of microcapsules aggregation 
during preparation of DPI formulations and detachment of microcapsules after 
aerosolization from the surface of carriers is shown schematically in Figure 2 which is 
adapted from reference (Hamishehkar et al., 2010).This figure shows the dry powder 
inhalation formulations containing the blend of microcapsules and carriers. It can be seen 
that there are not enough active sites on the surface of spray dried mannitol and freeze dried 
mannitol for microcapsules to be deposited on, so carriers cannot disaggregate 
microcapsules. In the case of sieved sorbitol, microcapsules immersed on the surface of 
carrier and did not detach easily from its surface after aerosolization. Therefore in spite of 
better emission of microcapsules from the formulation containing sieved sorbitol, the FPF of 
the drug decreased. In this article, sieved mannitol showed higher FPF for insulin-loaded 
PLGA microparticles due to its appropriate surface roughness characteristics. 
6.4. Fine carrier particles 
The addition of fine particles to DPI formulations was shown to improve the inhalation 
efficiency of drugs (Zeng et al., 1998; Lucas et al., 1998). Islam et al. confirmed that the 
presence of fine lactose associated with large carriers or added as an excipient, played a key 
role in the drug dispersion process in this study (Islam et al., 2004). Similar observations 
were made by Louey et al. using salbutamol sulphate with various lactose carriers (Louey et 
al., 2003). The addition of ternary components like magnesium stearate and leucine (French 
et al., 1996; Islam et al., 2004; Staniforth, 1996) has also enhanced drug dispersion by 
decreasing the cohesive forces between drug particles. The addition of 10% fine carriers 
(lactose, glucose, mannitol and sorbitol) in the interactive mixtures of salmeterol xinafoate 
and coarse carriers demonstrated the same conclusion that fines enhance the detachment of 
the drug from the large carriers (Adi et al., 2007). On the other hand, the opposite results 
have been concluded about the role of fines from few studies. It was reported that the 
concentration of added fine lactose has to be carefully controlled such that a desired 
dispersibility of the drug can be achieved without substantially affecting powder flow 
properties (Zeng et al., 1998). The presence of ‘‘fines’’ tend to inhibit flow because fines can 
fit into the voids between larger particles and encourage packing and consequent powder 
densification, and fines are inherently poor flowing (Augsburger, 1974) due to various 
surface forces (Hickey et al., 2007) and high cohesive energy. It was recently reported that 
the presence of fines caused a decrease in FPF (Steckel et al., 2004; Hamishehkar et al., 2010). 
Also the use of micronized fine carrier may introduce extra amorphous content to the 
powder because a large portion of micronized lactose is in the amorphous form, which is 
thermodynamically unstable and will convert to the more stable crystalline form on 
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exposure to moisture (Saleki-Gerhardt et al., 1994). Such a transformation is likely to change 
the performance characteristics of the bulk powder, such as flowability and drug dispersion 
(Ward et al., 1994). 
 
 
Figure 2. Schematic representation of the role of carrier surface asperities on the drug entrapment and 
its fluidization capabilities adapted from reference (Hamishehkar et al., 2010). 
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6.5. Carrier crystallinity 
The amorphous part shows a higher surface adhesion energy compared to crystalline 
surfaces (Young et al., 2004). As a result of increase in adhesion energy, poor deaggregation 
of drug particles is observed (Podczeck et al., 1997). Therefore it can be hypothesized that, 
the presence of amorphous material may cause problems, for example, due to the fusion of 
particles, resulting in poor dispersion (Young et al., 2004; Ward et al., 1995; Podczeck et al., 
1997). In addition, the amorphous regions can present difficulties such as decreased chemical 
stability (Pikal et al., 1978). Partially amorphous or unstable polymorphic forms and changes 
therein (Harjunen et al., 2002) make the interparticulate contact quite unpredictable and the 
powder formulation rather unstable (De Boer et al., 2003). It was reported that the maximum 
fine particle dose of terbutalinesulphate is obtained with the crystallized form of mannitol 
comparing to different polymorphs of mannitol (Saint-Lorant et al., 2007). Furthermore, 
previous reports have suggested increased amorphous content in DPI systems resulted in 
decreased aerosolization performance (Young et al., 2004; Ward et al., 1995). 
7. Lactose as the most frequently used carrier in DPIs  
Lactose, 4-(b-D-galactosido-)-D-glucose, can be obtained in either two basic isomeric forms, 
α and β-lactose, or as an amorphous form (Zeng et al., 2000). Historically, lactose 
monohydrate was an obvious choice for use as a carrier excipient. Lactose accompanying 
with glucose and mannitol is allowed as carriers in DPIs by the US Food and Drug 
Administration department (Labiris et al., 2003).Lactose is the most common and frequently 
used carrier in DPIs formulations and nowadays various inhalation grades of lactose with 
different physico-chemical properties are available on the market. The advantages of lactose 
are its well-investigated toxicity profile, physical and chemical stability, compatibility with 
the drug substance, its broad availability and relatively low price (Steckel et al., 2004; Pilcer 
et al., 2010).α-lactose monohydrate is the most common lactose grade used in the inhalation 
field.Almost all DPI formulations on the market are based on a-lactose monohydrate as a 
carrier. Therefore, wealth of literatures refers to the optimization of lactose carrier particles 
for better inhalation performance. More than 250 articles have been published in the past 40 
years regarding the role of lactose in adhesive mixtures used in DPIs. However, in spite of 
these extensive investigations, the relationship between physico-chemical properties of the 
lactose in adhesive mixtures and the performance of the DPIs remains largely indistinct 
(Marriott et al., 2012). 
8. Lactose engineering for application in DPIs  
8.1. Surface modification 
Iida et al. prepared lactose carrier particles for dry powder inhalations by its surface 
modification with aqueous ethanol solution and evaluated the inhalation efficiency of 
salbutamol sulfate from its mixture with modified lactose. The degree of adhesion between 
drug particles and carrier particles and the separation characteristics of drug particles from 
carrier particles in air flow were assessed by the ultracentrifuge separation and the air jet 
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sieve methods, respectively. It was shown that the average adhesion force between the surface-
treated lactose carrier and drug particles was considerably lower than that of powder mixed 
with the un-treated lactose carrier, indicating better drug separation from carrier and 
consequently an improvement of in vitro inhalation properties. The authors claimed that 
surface-smoothing of lactose by aqueous ethanol solution resulted a well balanced drug-carrier 
adhesion force so that the drug particles could be emitted together with the carrier particles 
and efficiently separated in airflow after emission(Iida et al., 2003). Fine lactose particles were 
immobilized on the lactose surface by spray coating with liquid suspensions consisting of 
micronized lactose dispersed in isopropyl alcohol and/or water mixtures to modify surface of 
lactose. The produced lactose was used as a carrier in the formulation of inhalable salbutamol 
sulfate powder. It was found that the roughness of the lactose surface established by 
immobilization of fine lactose increased the FPF and dispersibility of the drug. The authors 
claimed that unlike crevices and valleys, these microscopic undulations did not accommodate 
the drug particles and instead enhanced the detachment of drug from the lactose surface and 
improved the drug inhalation efficiency (Chan et al., 2003). Spray dried amorphous, spray 
dried crystallized and fluidized bed granulated lactose were prepared and used as carrier for 
inhalation of pranlukast hydrate. Fluidized bed granulated lactose emitted drug particles 
effectively from the inhalation device, whereas most part of drug captured in the upper stage 
of twin impinger, resulting in lower inhalation efficiency, due to strong adhesion of drug to 
the carrier lactose. The spray dried amorphous lactose, smoothed sphere particle, did not so 
improve the inhalation efficiency as expected, because of fairly strong adhesion between 
drug and lactose particles. But the spray dried crystallized lactose having lots of 
microscopical projection on its surface increased the respirable particle percent of the 
emitted particles. The conclusion was that the surface roughness should be optimized to 
gain improved inhalation efficiency of particles (Kawashima et al., 1998). In the other study, 
a Wurster fluidized bed was used for surface-coating of lactose particles with lactose 
aqueous solution containing hydroxypropyl methyl cellulose. The authors could be able to 
increase the inhalation performance of salbutamol sulfate 2.5 times more than commercial 
lactose  (Pharmatose® 200M) and reported that surface coating of carrier particles may be an 
effective technique for improving the inhalation performance of DPI (Iida et al., 
2005).Lactose carrier particles were layered with vegetable magnesium stearate by physical 
mixing and their effect of on the dry powder inhalation properties of salbutamol sulfate was 
investigated. The in vitro inhalation performance of drug was enhanced compared with the 
powder mixed with unlayered lactose carrier. It was stated that using this surface layering 
system would thus be valuable for increasing the inhalation properties of dry powder 
inhalation (Iida et al., 2004). For example, increasing the surface smoothness of lactose 
carrier particles was shown to improve the potentially respirable fraction of albuterol sulfate 
from the Rotahaler® (Littringer et al., 2012). 
8.2. Shape modification 
Lactose crystallization from Carbopol gel in different conditions (named Carbo lactose) 
produced a more regular shape lactose with smoother surface as compared with the control 
lactose. The Carbo lactose caused a higher and reproducible salbutamol sulphate emission 
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and FPF after aerosolisation via a Rotahaler® tested in multi-stage impinge. It was concluded 
that engineered crystal growth under controlled conditions can enhance the potential 
inhalable fraction of drug from dry powder inhalers (Zeng et al., 2001).More recently, the 
use of more elongated crystals of lactose was also found to produce a higher inhalation 
efficiency of albuterol sulfate(Zeng et al., 2000).However, the improvement in drug 
dispersion that can be achieved by increasing the elongation ratio of the carrier particles is 
limited (Zeng et al., 2001).  
8.3. Composite lactose 
Lactose carrier particles were prepared by fusing sub units of lactose (either2, 6 or 10 μm 
prepared by spray drying) in saturated lactose slurry, sieve fractioned to obtain a 63–90 μm 
carriers and used for inhalation of salbutamol sulfate. The surface morphology and physico-
chemical properties of the composite carriers were considerably different from regular α-
lactose monohydrate.In all cases the composite carriers resulted in improved drug aerosol 
performance. It was suggested that composite based carriers are a potential route to control 
drug–carrier adhesion forces and variability thus allowing more precise control of 
formulation performance (Young et al., 2009 ). 
8.4. Engineered lactose-mannitol mixture 
Mannitol and lactose were co-crystallised to prepare crystals with more desirable 
characteristics than either lactose or mannitol alone appropriate for application as carriers in 
the formulations of salbutamol sulfate DPIs. In vitro deposition evaluation showed that 
crystallized carriers resulted more efficient delivery of salbutamol sulphate compared to 
formulations containing commercial grade carriers. It was concluded that simultaneous 
crystallization of lactose-mannitol can be a new approach to enhance inhalation 
performance of DPI formulations (Kaialy et al., 2012). 
9. Mannitol 
Because of clinical considerations lactose or other sugars cannot be used for drug delivery to 
diabetic patients. Moreover, for some drugs, e.g., formoterol, or for specific applications, 
e.g., peptide or protein drugs, lactose monohydrate may not be the carrier of choice due to 
its reducing sugar function that may interact with functional groups of the drug or the 
protein (Patton et al., 1992)In addition, lactose monohydrate is produced from bovine or 
with bovine-driven additives so that the transmissible spongiform encephalopathy (TSE) is 
still an issue for this compound (European Commission-Health & Consumer Protection 
Directorate, 2002)Lactose intolerance is a problem that necessitates the patient to use lactose-
free formulations (Glasnapp, 1998).It is therefore logical to look for substitute carriers that 
still possess the positive aspects but overcome the above mentioned drawbacks of lactose 
monohydrate (Hamishehkar et al., 2010). Mannitol, a hexahydric alcohol, has been mainly 
used as a pharmaceutical excipient. Its potential use as a carrier for aerosol delivery has 
been reported (Tee et al., 2000; Steckel et al., 2004). Mannitol does not have a reducing sugar 
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function, is less hygroscopic than lactose (Saint-Lorant et al., 2007)and gives a suitable sweet 
after-taste which has a benefit to patients confirming them that a dose has been properly 
administered (Kaialy et al., 2010).Mannitol proved to be the most promising candidate for 
this application than the more hygroscopic sugar alcohols such as sorbitol, xylitol and 
maltitol. D-mannitol is currently marketed in some countries as a pulmonary diagnostic dry 
powder inhalation aerosol (AridolTM) and as a therapeutic dry powder inhalation aerosol for 
the treatment of cystic fibrosis and chronic bronchitis (BronchitolTM) which are recently 
approved by US food and drug administration office and a European regulatory committee, 
respectively(Mansour et al., 2010).Spherical mannitol particles used in AridolTM were 
produced by spray drying (Tang et al., 2009).A DPI formulation for inhalation of 
ciprofloxacin hydrochloride (an antibacterial fluoroquinolone) was prepared by its co-spray 
drying with different percentages of mannitol. The combination formulation containing 50% 
(w/w) mannitol showed the best inhaltion performance, good stability and lowest particle 
cohesion (as measured by colloid probe microscopy). It was proposed that the combination 
of co-spray-dried mannitol and ciprofloxacin from a DPI is an attractive approach to 
promote mucous clearance in the respiratory tract while simultaneously treating local 
chronic infection, such as chronic obstructive pulmonary disease and cystic fibrosis (Adi 
et al., 2010). Spray drying method was used to prepare several types of mannitol differ in 
shape and surface roughness. In this study besides the introducing the spray drying method as 
a proper technique for preparation of mannitol as a carrier for inhlation purposes, it was 
concluded that the highest fine particle fraction was achieved with carrier particles of spherical 
shape and a rough surface (Littringer et al., 2012).Despite the above mentioned study, in 
another study it was shown that the use of elongated mannitol as the carrier particle produced 
improved DPI performance. It was also indicated that mannitol particles crystallized from 
either acetone or ethanol (α-mannitol) showed the best aerosolisation performance while 
poorest aerosolisation performance was obtained from grounded mannitol (β-mannitol) 
(Kaialya et al., 2011).The same research group in another study again reported the better 
inhalation performance of salbutamol sulfate from elongated mannitol. In this study mannitol 
was crystallized from different binary mixtures of acetone/water and its carrier role in DPI 
formulations of salbutamol sulfate was investigated (Kaialy et al., 2010).Mannitol particles, 
produced by spray drying, have been used commercially (AridolTM) in bronchial provocation 
test (mannitol particle itself as an active ingredient not as a carrier). In a study, a confined 
liquid impinging jets (CLIJs) followed by jet milling was applied and introduced as an 
alternative method for spray drying. Although the inhalation performance of mannitol 
particles prepared by CLIJ method was not higher than those prepared from spray drying 
method (FPF 30% for particles prepared by CLIJ method compared to FPF 47% of those 
prepared by spray dying method) but CLIJ method offers several advantages. A main 
advantage of using the CLIJ method is that it can be scaled up with an acceptable yield as the 
precipitate can be largely collected and recovered on a filter, compared with spray drying 
which has a low collection efficiency for fine particles below 2 μm (Tang et al., 2009).Lactose, 
mannitol and glucose were used as the carriers in the formulations of inhalation powders of 
budesonide and salbutamol sulphate. The highest respirable fraction of drugs were achieved 
when mannitol was used as the carrier (Harjunen et al., 2003). 
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10. Sorbitol 
Reducing sugars such as lactose may have an impact on the stability of proteins and 
peptides (Li et al., 1996; Dubost et al., 1996). Actuality, the use of lactose with protein 
powders may cause a reaction with lysine residues present in the protein, generating 
lactosylated protein molecules (Cryan, 2005).In this case, polyols such as sorbitol can play a 
crucial role in the formulation of respirable protein powder. Sorbitol can also serve as 
stability enhancers during processing. It was reported that the stability of interferon β to jet 
milling, required to produce a respirable powder, was found to be dependent on the 
presence of sorbitol in the formulation (Platz et al., 1991; Platz et al., 1994).Sorbitol showed a 
comparable inhalation outcome for salbutamol sulfate with lactose and mannitol but failed 
to produce efficient dispersion of drug (FPF less than10%) (Tee et al., 2000).  
11. Erythritol 
Erythritol, a meso-compound of 1,2,3,4-butanetetrol, is a natural occurring sugar alcohol 
existing in various fruits and fermented foods, as well as in body fluids of humans and 
animals. Industrially, it is prepared by glucose fermentation (Lopes Jesus et al., 2010). 
Erythritol has been administered as a suitable excipient in pharmaceutical formulations due 
to its thermal stability, very low hygroscopicity (Cohen et al., 1993) sweetness taste, low 
toxicity (Munro et al., 1998) and high compatibility with drugs (Endo et al., 2005; Gonnissen 
et al., 2007).Due to above desirable characteristics, erythritol was recently entered in the 
European Pharmacopoiea (Traini et al., 2006). Endo et al. used erythritol as carrier in the DPI 
formulation of glucagon, a key regulatory element of glycogen metabolism which is known 
to be effective in the clinical treatment of hypoglycemia and the maintenance of normal 
circulating glucose levels in patients with total pancreatectomy. This hormone has been 
restricted to parenteral administration. The in vitro and in vivo studies were indicated the 
suitability of erythritol for application in DPI formulation. Moreover, it was claimed that 
this dry powder inhalation of glucagon can be administered to the clinical treatment of 
hypoglycemia, and the maintenance of normal circulating glucose levels in patients with 
total pancreatectomy (Endo et al., 2005). In a comparative study, erythritol andlactose 
monohydrate were used as carriers in the DPI formulation of salbutamol sulfate. Drug-
carrier adhesion was measured using atomic force microscope colloid probe technique and 
showed a higher adhesion force for erythritol than lactose. Consequently lower inhalation 
performance of salbutamol sulfate was resulted from DPI formulations containing erythritol 
than lactose. However, it was concluded that even though erythritol may show a reduced 
DPI functionality, with this drug, it may offer some potential advantages in terms of its 
reproducible chemical structure and stability (Traini et al., 2006). 
12. Trehalose 
Trehalose dihydrate is a disaccharide sugar and crystalline hydrate like lactose. However, 
trehalose dihydrate is a non-reducing sugar and lactose monohydrate is a reducing sugar. 
As a reducing sugar, it participates in solid-state chemical degradation by the Maillard 
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reaction with certain types of small molecular weight drugs (such as formoterol and 
budesonide) and polypeptide/protein-type drugs. Therefore, some attempts have been 
carried out on the application of trehalose in the formulation of DPIs. In a study, trehalose 
was used as a carrier for DPI formulation of albuterol sulfate, ipratropium bromide 
monohydrate, disodium cromoglycate, and fluticasone propionate (Mansour et al., 
2010).The highest inhalation performance was reported for the blend of albuterol and 
ipratropium with trehalose dihydrate in comparison with lactose monohydrate and 
mannitol (Cline et al., 2002).  
13. Other carriers 
Recently, the feasibility of using pollen-shape hydroxyapatite particles as carrier in DPI 
formulation of budesonide is investigated. The hydroxyapatite carriers showed better 
flowability and capability of higher drug attachment than commonly used lactose carrier 
with similar size range. Consequently, DPI formulations with hydroxyapatite carriers gave 
higher drug emission and respirable fraction than traditional lactose carriers (Hassan et al., 
2010). Many different non-lactose carriers have been investigated, such as cyclodextrins, 
dextrose, glucose monohydrate, maltitol, maltose, raffinosepentahydrate and 
xylitol.Anhydrous glucose is already used in the marketed product Bronchodual®  
(Boehringer) (Pilcer et al., 2010).Sucrose, trehalose and raffinose are non-reducing sugars 
and as such have the advantage that they will not undergo the Maillard browning reaction 
with proteins (Ógáin et al., 2011). But in contrast to lactose monohydrate which was found 
to only take up moisture on its surface, and showing only a small reduction in its FPF after 
storage at 75% RH (Young et al., 2007; Zeng etal., 2007), a main difficulty with these sugars, 
especially with the more hygroscopic substances – sorbitol, maltitol and xylitol – has 
attributed to their sensitivity to humidity. In fact, the capillary forces, arisen from the 
dynamic condensation of water molecules onto particle surfaces, seem to be less prominent 
with mannitol and lactose as carriers, probably because of their less hygroscopic characteristics 
than the other carbohydrates (Zeng et al., 2007; Young et al., 2007). However, it was proposed 
that the difficulties arising from their hygroscopicity can be overcome by adding an ultrafine 
hydrophobic excipient to the powder blend (Steckel et al., 2004).Comparing the different forms 
of mannitol, lactose and maltitol mixed with terbutaline sulfate resulted in higher FPF with 
crystallized mannitol for terbutaline sulfate (Saint-Lorant et al., 2007).Hooton et al, used beta 
cyclodextrin, lactose, raffinose, trehalose and xylitol for the formulation of salbutamol sulfate 
DPI and applied the cohesive-adhesive balance technique for analyzing quantitative AFM 
measurements to interpret inhalation behavior of drug. The rank order of the FPF of the 
salbutamol sulfate based carrier DPI formulations was beta cyclodextrin> lactose 
>raffinose>trehalose> xylitol which had a linear correlation with cohesive-adhesive ratios of 
the AFM force measurements (Hooton et al., 2006).  
14. Large porous particles 
A new type of aerosol formulation is the large porous hollow particles. These particles have 
the mean diameters >5 μm and mass densities <0.1g/cm3 (Edwards et al., 1997). Although 
 
The Role of Carrier in Dry Powder Inhaler 55 
these particles have large geometric diameters because of their low density, they exhibit 
aerodynamic diameters comparable to smaller particles having higher densities (Koushik et 
al., 2004). They may be ideal for pulmonary drug delivery because of their low density and 
large surface area which causes excellent dispersibility (Labiris et al., 2003). Furthermore, 
their large geometric size may reduce clearance by macrophage action, thereby improving 
the bioavailability of inhaled pharmaceuticals (Musante et al., 2002).To show the ability of 
large porous aerosols to increase systemic bioavailability as well as to provide sustained-
release capability in the lungs, Edwards et al. encapsulated insulin into a biodegradable 
polymers and indicated the better inhalation performance and controlled-release capability of 
these particles in the lung (Edwards et al., 1997).Ungaro et al. confirmed the same observations 
with delivery of insulin into rat lung by preparation of PLGA large porous particle with the 
aid of cyclodextrins (Ungaro et al., 2009).These particles can be prepared using polymeric or 
nonpolymeric excipients, by solvent evaporation and spray-drying techniques (Edwards et al., 
1998). Pulmospheres™ is an example which is made of phosphatidylcholine, the primary 
component of human lung surfactant (Labiris et al., 2003). In two interesting studies, highly 
porous large biodegradable polymeric particles were fabricated using ammonium bicarbonate 
as an effervescent porogen (Ungaro et al., 2010; Yang et al., 2009). 
15. Conclusion 
The number of diseases that are being considered candidates for the aerosol therapy has 
increased considerably. Until recently, asthma and chronic obstructive pulmonary diseases 
were only the apparent examples of diseases that could be treated via drug delivery to 
lungs. But now other pulmonary diseases such as cystic fibrosis, lung cancer and pulmonary 
infectious diseases and also systemic disorders such as diabetes, cancer, neurobiological 
disorders are considered to be managed by pulmonary drug delivery. Interest in DPIs has 
increased in the last decade due to its numerous advantages over other pulmonary drug 
delivery dosage forms. Currently, the inhalation performance of DPIs are being improved 
by changing formulation strategy, drug and carrier particle engineering. Regarding 
formulation development, micronised drug particles are cohesive with poor flow properties. 
Addition of large carrier particles into powders to enhance their flow characteristics has 
been an appropriate approach. The main goal in the inhalation field is to obtain 
reproducible, high pulmonary deposition which can be highly effected by physico-chemical 
characteristics of carrier. This could be achieved by successful carrier selection and careful 
process optimization. Technologies for engineering carrier particle shape, density, and size 
will continue to develop to enhance the effectiveness of pulmonary drug formulations. This 
approach may enable more drugs to be delivered through this route for local treatment of 
lung diseases or systemic therapy. 
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